Patients with Newly Diagnosed Malignant Brain Tumors Now Eligible for Surgically Targeted Radiation Therapy TEMPE, Ariz. -- GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced that the U.S. Food and...
After nearly 10 years and more than 12,000 patients treated following its FDA approval for prostate cancer treatment, sufficient scientific data and patient-reported evidence suggest that Cesium-131 delivers equivalent to, or superior outcomes compared to Iodine and...
2017 saw the publication and dissemination of multiple new studies, including long-term results, and guidelines for prostate cancer treatment. Yet as the year passed by, we were surprised to discover that many clinicians remained unaware of the data and its ability to...
Study Demonstrates 100% Freedom from Local Progression Rate & 0% Rate of Radionecrosis RICHLAND, Wash., June 20, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope...
Change in healthcare can be agonizingly slow. The scientific rigors and huge financial investments needed to bring novel life saving therapies help ensure physicians do no harm. However, in the grinding shift from fee for service to value-based care it is high time to...
The following article originally appeared in the Winter/Spring 2017 MicroCap Review Magazine. A small company in Richland, WA is dedicated to making a difference in the lives of patients diagnosed with different forms of cancer. Isoray Medical, Inc. [NYSE MKT:ISR] has...
Isoray is excited to be supporting the upcoming Society of Gynecologic Oncology (SGO) annual meeting, which will be held March 12-15 in National Harbor, Maryland. The SGO meeting serves as a forum on women’s cancer, providing the latest clinical updates and research...
The Society of Thoracic Surgeons Annual Meeting is the pinnacle of scientific education and new research results delivery in the global cardiothoracic community. Included within this community are the surgeons treating lung cancer patients. Through this lens, Isoray...
The successes Isoray Medical celebrated, and the milestones attained in 2016, have set a strong foundation that will allow us to catapult forward into 2017. We expect to continue to build on these successes in 2017, as we leverage our new web presence to share the...
It has been an amazing year for the IsoRay team. The last 12 months have been marked by the release of groundbreaking data for our Cesium-131 Brachytherapy, the realignment of our management team, and a new web presence to maximize our reach and convey our messaging....